-- Update from Ongoing Phase 1 Clinical Trial of EO-3021 Now Expected Mid-2024 ---- Expanding EO-3021 Clinical Development Program to Include Combination Strategy -- -- Announcing HER3-targeting ADC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback